Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavisant for Excessive Daytime Sleepiness in Parkinson's Disease
NCT03194217Phase 2Completed
- Sponsor
- BenevolentAI
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bavisant in Excessive Daytime Sleepiness (EDS) (4 arms), sponsored by BenevolentAI. Primary endpoint: Epworth Sleepiness Scale at 6 weeks. Started Nov 2017; status: completed.
02
Drugs
bavisant
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT03194217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194217.